ReviewCurrent cardiology reports2024
Impact of Visceral and Hepatic Fat on Cardiometabolic Health.
Review in Current cardiology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Visceral fat score predicts diabetic kidney disease: analysis of 20 years of U.S. NHANES data.Renal failure · 2026Article
- Metabolic dysfunction-associated steatotic liver disease-a review of the cardiometabolic perspectives and treatments in children.International journal of obesity (2005) · 2026Review
- Jabuticaba (Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study.Clinical and molecular hepatology · 2026Article
- Sleep Maintenance Insomnia in Older Adults: Cardiometabolic Comorbidities and Evidence of Antiviral Pathways Activation from Blood Transcriptome and dsRNA Expression Analyses.International journal of molecular sciences · 2026Article
- Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications.Biomedicines · 2026Review
- Ultrasound and MRI abdominal fat distribution and its associations with metabolic conditions in adults with abdominal obesity.Diabetes, obesity & metabolism · 2026Article
- Specific Fat Depots and Cardiometabolic Risk and Insulin Resistance in Children With Obesity.Pediatric obesity · 2026Article
- Triglyceride glucose index and modified triglyceride glucose indices are instrumental to optimize 3P medical management for postpartum cardiovascular disease.The EPMA journal · 2026Article
- Longitudinal analysis of body compositions following Roux-en-Y gastric bypass.Langenbeck's archives of surgery · 2026Article
- Association of obesity-metabolic phenotypes with coronary artery disease prevalence: interaction and exploratory mediation analyses of high-sensitivity C-reactive protein.Frontiers in cardiovascular medicine · 2026Article
- Type 2 diabetes mellitus and incident carotid atherosclerosis: a retrospective cohort study on composite indices.Frontiers in endocrinology · 2026Article
- Impact of an MRI Body Fat Imaging Report on Obesity-Related Cardiometabolic Risk: Findings From the BODY-REAL Study, A Randomized Trial.Obesity science & practice · 2025Article
- Targeting Metabolic Dysregulation in Obesity and Metabolic Syndrome: The Emerging Role of N-Acetylcysteine.Metabolites · 2025Review
- Association of weight-adjusted-waist index with all-cause and cardiovascular mortality in hypertension: a prospective cohort study.BMC public health · 2025Article
- The Perceptions of and Attitudes Toward Obesity in Bulgarian Adults with a BMI ≥ 25.0 kg/mNutrients · 2025Article
- Visceral adiposity loss is associated with improvement in cardiometabolic markers: findings from a dietary intervention study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBody fat distribution plays a significant role in the cardiometabolic consequences of obesity. We review the impact of visceral and hepatic fat and highlight important interventions. RECENT
findingsSeveral epidemiologic studies have established a clear association between visceral fat and cardiovascular disease. The association between hepatic fat and cardiovascular disease is less clear with discordant results. Novel evidence demonstrates sodium glucose co-transporter-2 (SGLT2) inhibitors facilitate modest weight loss and reductions in ectopic fat depots in patient with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with decreased visceral/hepatic fat and reductions in MACE in populations with type 2 diabetes and with overweight/obesity. Clear associations between visceral fat and cardiometabolic outcomes have been established, whereas the impact of hepatic fat remains less clear. Lifestyle modification and pharmacologic interventions remain the initial therapies, while surgical intervention is associated with improved long-term outcomes. Emerging therapies have demonstrated a profound impact on body fat distribution and cardiometabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.